Transcleral Drainage of Subretinal Fluid, Anti-Vascular Endothelial Growth Factor, and Wide-Field Imaging-Guided Laser in Coats Exudative Retinal Detachment

Stanga, Paulo E; Jaberansari, Horj; Bindra, Mandeep Singh; Gil-Martínez, María; Biswas, Susmito

doi:10.1097/iae.0000000000000669

Cited by 36 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2016, Stanga et al [ 5 ] were the first to propose a new treatment multiple approach for stage 3 Coats disease combining three different procedures: transscleral drainage of SRF, intravitreal anti-VEGF injections, and laser photocoagulation of the nonperfused area of the retina.…”

Section: Discussionmentioning

confidence: 99%

“…In one case (Case 1), a triple therapy approach was performed as previously described by Stanga et al [ 5 ]: under general anesthesia, exudative subretinal fluid was drained transclerally by a 27-gauge needle mounted on a 5 ml syringe with the plunger removed. In order to avoid retinal damage, the needle was inserted perpendicularly to the sclera in the area having the higher amount of fluid (previously identified with binocular indirect ophthalmoscopy).…”

Section: Methodsmentioning

confidence: 99%

“…A new treatment approach for stage 3 Coats disease was described by Stanga et al [ 5 ], combining three different procedures such as transscleral drainage of SRF, intravitreal anti-VEGF injection, and retinal nonperfusion area laser photocoagulation. They reported their successful experience in 8 eyes of children with a variable follow-up from 9 to 60 months.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multiple Therapy Approach for Stage 3 Coats Disease: Long-Term Follow-Up

Mastropasqua

D’Aloisio

Stanga

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To assess long-term efficacy of a multiple therapy approach in the treatment and management of unilateral stage 3 Coats disease with exudative retinal detachment. Methods. 2 eyes of 2 young patients suffering from unilateral stage 3 Coats disease underwent a multiple therapy approach consisting of surgical drainage of exudative subretinal fluid + one simultaneous and up to one subsequent intravitreal injection of bevacizumab + multiple (up to 3) laser photocoagulation sessions of retinal nonperfusion areas and leaking Coats vasculature. Results. Complete reabsorption of SRF and retinal reattachment were observed in both cases over the follow-up. In no cases, we observed progression to phthisis bulbi. No bevacizumab-related complications were observed. Epiretinal membrane onset was detected in one eye at the end of follow-up. Conclusion. The management and treatment of this rare and degenerative disease in young subjects are still a challenge. The described technique is less invasive than conventional intraocular surgery and may be preferable to halt the devastating progression of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple Therapy Approach for Stage 3 Coats Disease: Long-Term Follow-Up

Mastropasqua

D’Aloisio

Stanga

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The increased levels of VEGF are speculated to result in an increased vascular permeability and formation of peripheral telangiectasias [ 12 , 13 ]. Recently, anti-VEGF therapy has been shown to exert a rapidly expanding role in the treatment of Coats’ disease [ 10 , 14 , 15 ]. The elevated VEGF levels in Coats’ disease decreased markedly after the injection of the anti-VEGF agent [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease

Zhang

Wang

et al. 2018

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

PurposeThe current treatment approaches for Coats’ disease by intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents (ranibizumab or conbercept) combined with laser therapy were evaluated for the efficacy during the treatment.MethodsThe medical records of 28 patients diagnosed with Coats’ disease followed by the treatment with intravitreal injection of anti-VEGF agents and laser therapies at Tianjin Medical University Eye Hospital and Hebei Eye Hospital during July 2012 and October 2017 were reviewed retrospectively. Clinical outcomes were recorded with a minimum follow-up of 6 months. The patients were divided into ranibizumab- and conbercept-treated groups, as well as based on age: pediatric and adult groups.ResultTwenty-eight patients were involved in this study. The average number of the injections was 2.82 ± 0.98. Laser photocoagulation was conducted in all patients, and the average number of lasers was 2.63 ± 0.74. The average follow-up period was 24.29 ± 9.85 months. Fourteen patients (50%) were stable, 12 (43%) patients were improved, and 2 patients (7%) showed recurred subretinal fluid and exudation. The final best corrected visual acuity (BCVA) increased markedly after intravitreal injection of ranibizumab or conbercept combined with laser therapy (p = 0.029, p = 0.009, respectively). The number of injections and lasers between conbercept and ranibizumab groups did not vary significantly (p = 0.160, p = 0.573, respectively). Nine patients (60%) in the ranibizumab-treated group and five (38%) in the conbercept-treated group reached a stable phase, and five (33%) and seven (54%) patients got the vision improved after treated with ranibizumab or conbercept, respectively. In pediatric and adult groups, the initial and final BCVA differed significantly (p = 0.03, p = 0.008, respectively). However, the injection number was remarkably different (p = 0.02), while the laser numbers did not have any markedly difference (p = 0.38).ConclusionIntravitreal injection of ranibizumab or conbercept combined with laser therapy is an effective therapeutic option in Coats’ disease. Moreover, the intravitreal injection of ranibizumab or conbercept had no significant adverse effects and appeared to offer visual improvement in Coats’ disease.

show abstract

“…In 2015, Chhablani and Balakrishnan [2] used a 26-G needle attached to a cannula under Chandelier assistance to drain SRF. Additionally, combined transscleral drainage of SRF with intravitreal bevacizumab and laser photocoagulation was proven effective in advanced Coats disease (stage 3) patients with exudative RD [20] .…”

mentioning

confidence: 99%

A Modified Technique for the Transconjunctival and Sutureless External Drainage of Subretinal Fluid in Bullous Exudative Retinal Detachment Using a 24-G i.v. Catheter

et al. 2017

View full text Add to dashboard Cite

Purpose: To present the use of a 24-G Optiva® i.v. catheter for external drainage of subretinal fluid (SRF) in bullous exudative retinal detachment (RD). Methods: Thirteen eyes with bullous exudative RD were included in our study. SRF drainage was accomplished via a transconjunctival scleral incision with a 24-G catheter followed by laser treatment, vitrectomy, or anti-VEGF treatment, as needed. Data on age, indications, visual acuities, the number of drainage times, drainage duration, complications, and fundoscopy were collected. Results: Two females and 11 males, with a mean age of 4.2 ± 2.7 years, were included. Surgical indications included exudative RD caused by Coats disease (12 eyes) and Sturge- Weber syndrome (1 eye). Successful drainage was achieved in all cases. The mean duration of the SRF drainage procedure was 63.5 ± 16.9 s. Except for 1 case of localized subretinal haemorrhage, no complications were noted. Conclusions: External drainage of SRF using a 24-G Optiva® i.v. catheter is safe, efficient, and useful.

show abstract

Transcleral Drainage of Subretinal Fluid, Anti-Vascular Endothelial Growth Factor, and Wide-Field Imaging-Guided Laser in Coats Exudative Retinal Detachment

Cited by 36 publications

References 14 publications

Multiple Therapy Approach for Stage 3 Coats Disease: Long-Term Follow-Up

Multiple Therapy Approach for Stage 3 Coats Disease: Long-Term Follow-Up

The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease

A Modified Technique for the Transconjunctival and Sutureless External Drainage of Subretinal Fluid in Bullous Exudative Retinal Detachment Using a 24-G i.v. Catheter

Contact Info

Product

Resources

About